In the past two decades, high-affinity nucleic acid aptamers have been developed for a wide variety of pure molecules and complex systems such as live cells. Conceptually, aptamers are developed by an evolutionary process, whereby, as selection progresses, sequences with a certain conformation capable of binding to the target of interest emerge and dominate the pool. This protocol, cell-SELEX (systematic evolution of ligands by exponential enrichment), is a method that can generate DNA aptamers that can bind specifically to a cell type of interest. Commonly, a cancer cell line is used as the target to generate aptamers that can differentiate that cell type from other cancers or normal cells. A single-stranded DNA (ssDNA) library pool is incubated with the target cells. Nonbinding sequences are washed off and bound sequences are recovered from the cells by heating cell-DNA complexes at 95 °C, followed by centrifugation. The recovered pool is incubated with the control cell line to filter out the sequences that bind to common molecules on both the target and the control, leading to the enrichment of specific binders to the target. Binding sequences are amplified by PCR using fluorescein isothiocyanate–labeled sense and biotin-labeled antisense primers. This is followed by removal of antisense strands to generate an ssDNA pool for subsequent rounds of selection. The enrichment of the selected pools is monitored by flow cytometry binding assays, with selected pools having increased fluorescence compared with the unselected DNA library. The procedure, from design of oligonucleotides to enrichment of the selected pools, takes ∼3 months.
Your institute does not have access to this article
Open Access articles citing this article.
Targeting loop3 of sclerostin preserves its cardiovascular protective action and promotes bone formation
Nature Communications Open Access 22 July 2022
Bone Research Open Access 23 May 2022
Scientific Reports Open Access 21 April 2021
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Tuerk, C. & Gold, L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249, 505–510 (1990).
Ellington, A.D. & Szostak, J.W. In vitro selection of RNA molecules that bind specific ligands. Nature 346, 818–822 (1990).
Ciesiolka, J. & Yarus, M. Small RNA-divalent domains. RNA 2, 785–793 (1996).
Hofmann, H.P., Limmer, S., Hornung, V. & Sprinzl, M. Ni2+-binding RNA motifs with an asymmetric purine-rich internal loop and a G-A base pair. RNA 3, 1289–1300 (1997).
Rajendran, M. & Ellington, A.D. Selection of fluorescent aptamer beacons that light up in the presence of zinc. Anal. Bioanal. Chem. 390, 1067–1075 (2008).
Geiger, A., Burgstaller, P., von der Eltz, H., Roeder, A. & Famulok, M. RNA aptamers that bind l-arginine with sub-micromolar dissociation constants and high enantioselectivity. Nucleic Acids Res. 24, 1029–1036 (1996).
Connell, G.J., Illangesekare, M. & Yarus, M. Three small ribooligonucleotides with specific arginine sites. Biochemistry 32, 5497–5502 (1993).
Famulok, M. Molecular recognition of amino acids by RNA-aptamers: an l-citrulline binding RNA motif and its evolution into an l-arginine binder. J. Am. Chem. Soc. 116, 1698–1706 (1994).
Harada, K. & Frankel, A.D. Identification of two novel arginine binding DNAs. EMBO J. 14, 5798–5811 (1995).
Wallis, M.G. et al. In vitro selection of a viomycin-binding RNA pseudoknot. Chem. Biol. 4, 357–366 (1997).
Wallace, S.T. & Schroeder, R. In vitro selection and characterization of streptomycin-binding RNAs: recognition discrimination between antibiotics. RNA 4, 112–123 (1998).
Nieuwlandt, D., Wecker, M. & Gold, L. In vitro selection of RNA ligands to substance P. Biochemistry 34, 5651–5659 (1995).
Williams, K.P. et al. Bioactive and nuclease-resistant l-DNA ligand of vasopressin. Proc. Natl Acad. Sci. USA 94, 11285–11290 (1997).
Tuerk, C., MacDougal, S. & Gold, L. RNA pseudoknots that inhibit human immunodeficiency virus type 1 reverse transcriptase. Proc. Natl Acad. Sci. USA 89, 6988–6992 (1992).
Chen, H., McBroom, D.G., Zhu, Y.-Q., Gold, L. & North, T.W. Inhibitory RNA ligand to reverse transcriptase from feline immunodeficiency virus. Biochemistry 35, 6923–6930 (1996).
Dang, C. & Jayasena, S.D. Oligonucleotide inhibitors of Taq DNA polymerase facilitate detection of low copy number targets by PCR. J. Mol. Biol. 264, 268–278 (1996).
Kubik, M.F., Stephens, A.W., Schneider, D., Marlar, R.A. & Tasset, D. High-affinity RNA ligands to human α-thrombin. Nucleic Acids Res. 22, 2619–2626 (1994).
Jellinek, D. et al. Potent 2′-amino-2′-deoxypyrimidine RNA inhibitors of basic fibroblast growth factor. Biochemistry 34, 11363–11372 (1995).
Green, L.S. et al. Inhibitory DNA ligands to platelet-derived growth factor B-chain. Biochemistry 35, 14413–14424 (1996).
Wiegand, T.W. et al. High-affinity oligonucleotide ligands to human IgE inhibit binding to Fc epsilon receptor I. J. Immunol. 157, 221–230 (1996).
Davis, K.A., Lin, Y., Abrams, B. & Jayasena, S.D. Staining of cell surface human CD4 with 2′-F-pyrimidine-containing RNA aptamers for flow cytometry. Nucleic Acids Res. 26, 3915–3924 (1998).
Smith, D., Kirschenheuter, G.P., Charlton, J., Guidot, D.M. & Repine, J.E. In vitro selection of RNA-based irreversible inhibitors of human neutrophil elastase. Chem. Biol. 2, 741–750 (1995).
Mallikaratchy, P., Stahelin, R.V., Cao, Z., Chob, W. & Tan, W. Selection of DNA ligands for protein kinase C-δ. Chem. Commun. 3229–3231 (2006).
Mendonsa, S.D. & Bowser, M.T. In Vitro selection of high-affinity DNA ligands for human IgE using capillary electrophoresis. Anal. Chem. 76, 5387–5392 (2004).
Morris, K.N., Jensen, K.B., Julin, C.M., Weil, M. & Gold, L. High affinity ligands from in vitro selection: complex targets. Proc. Natl Acad. Sci. USA 95, 2902–2907 (1998).
Blank, M., Weinschenk, T., Priemer, M. & Schluesener, H. Systematic evolution of a DNA aptamer binding to rat brain tumor microvessels. selective targeting of endothelial regulatory protein pigpen. J. Biol. Chem 276, 16464 (2001).
Hicke, B.J. et al. Tenascin-C aptamers are generated using tumor cells and purified protein. J. Biol. Chem. 276, 48644–48654 (2001).
Wang, C. et al. Single-stranded DNA aptamers that bind differentiated but not parental cells: subtractive systematic evolution of ligands by exponential enrichment. J. Biotechnol. 102, 15–22 (2003).
Cerchia, L. et al. Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase. PLoS Biol. 3, 0697–0704 (2005).
Shangguan, D. et al. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc. Natl Acad. Sci. USA 103, 11838–11843 (2006).
Tang, Z. et al. Selection of aptamers for molecular recognition and characterization of cancer cells. Anal. Chem. 79, 4900–4907 (2007).
Chen, H.W. et al. Molecular recognition of small-cell lung cancer cells using aptamers. ChemMedChem 3, 991–1001 (2008).
Sefah, K. et al. Molecular recognition of acute myeloid leukemia using aptamers. Leukemia 23, 235–244 (2009).
Shangguan, D. et al. Identification of liver cancer-specific aptamers using whole live cells. Anal. Chem. 80, 721–728 (2008).
Pan, W. et al. Isolation of virus-neutralizing RNAs from a large pool of random sequences. Proc. Natl Acad. Sci. USA 92, 11509–11513 (1995).
Kumar, P.K.R. et al. Isolation of RNA aptamers specific to the NS3 protein of hepatitis C virus from a pool of completely random RNA. Virology 237, 270–282 (1997).
Misono, T.S. & Kumar, P.K.R. Selection of RNA aptamers against human influenza virus hemagglutinin using surface Plasmon resonance. Anal. Biochem. 342, 312–317 (2005).
Gopinath, S.C.B. et al. An RNA aptamer that distinguishes between closely related human influenza viruses and inhibits haemagglutinin-mediated membrane fusion. J. Gen. Virol. 87, 479–487 (2006).
Tang, Z., Parekh, P., Turner, P., Moyer, R.W. & Tan, W. Generating aptamers for recognition of virus-infected cells. Clin. Chem. 55, 813–822 (2009).
Bruno, J.G. & Kiel, J.L. In vitro selection of DNA aptamers to anthrax spores with electrochemiluminescence detection. Biosens. Bioelectron. 14, 457–464 (1999).
Hamula, C.L.A., Zhang, H., Guan, L.L., Li, X.-F. & Le, C. Selection of aptamers against live bacterial cells. Anal. Chem. 80, 7812–7819 (2008).
Floege, J. et al. Novel approach to specific growth factor inhibition in vivo: antagonism of platelet-derived growth factor in glomerulonephritis by aptamers. Am. J. Pathol. 154, 169–179 (1999).
Ostendorf, T. et al. The effects of platelet-derived growth factor antagonism in experimental glomerulonephritis are independent of the transforming growth factor–ß system. J. Am. Soc. Nephrol. 13, 658–667 (2002).
White, R.R. et al. Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2. Proc. Natl Acad. Sci. USA 100, 5028–5033 (2003).
Conrad, R. & Ellington, A.D. Detecting immobilized protein kinase C isozymes with RNA aptamers. Anal. Biochem. 242, 261–265 (1996).
Murphy, M.B., Fuller, S.T., Richardson, P.M. & Doyle, S.A. An improved method for the in vitro evolution of aptamers and applications in protein detection and purification. Nucleic Acids Res. 31, e110 (2003).
Ireson, C.R. & Kelland, L.R. Discovery and development of anticancer aptamers. Mol. Cancer Ther. 5, 2957–2962 (2006).
Da Pieve, C., Williams, P., Haddleton, D.M., Palmer, R.M.J. & Missailidis, S. Modification of thiol functionalized aptamers by conjugation of synthetic polymers. Bioconjug. Chem. 21, 169–174 (2010).
Hicke, B.J. et al. DNA aptamers block L-selectin function in vivo. J. Clin. Invest. 98, 2688–2692 (1996).
Smith, J.E. et al. Aptamer-conjugated nanoparticles for the collection and detection of multiple cancer cells. Anal. Chem. 79, 3075–3082 (2007).
Kang, W.J., Chae, J.R., Cho, Y.L., Lee, J.D. & Kim, S. Multiplex imaging of single tumor cells using quantum-dot-conjugated aptamers. Small 5, 2519–2522 (2009).
Chu, T.C. et al. Aptamer:toxin conjugates that specifically target prostate tumor cells. Cancer Res. 66, 5989–5992 (2006).
Primo, C.D. et al. Systematic screening of LNA/2'-O-methyl chimeric derivatives of a TAR RNA aptamer. FEBS Lett. 581, 771–774 (2007).
Schmidt, K.S. et al. Application of locked nucleic acids to improve aptamer in vivo stability and targeting function. Nucleic Acids Res. 32, 5757–5765 (2004).
Gregory Biesecker, G., Dihel, L., Enney, K. & Bendele, R.A. Derivation of RNA aptamer inhibitors of human complement C5. Immunopharmacology 42, 219–230 (1999).
Golden, M.C, Collins, B.D., Willis, M.C. & Koch, T.H. Diagnostic potential of PhotoSELEX-evolved ssDNA aptamers. J. Biotechnol. 81, 167–178 (2000).
Cox, J.C. & Ellington, A.D. Automated selection of anti-protein aptamers. Bioorg. Med. Chem. 9, 2525–2531 (2001).
Kim, S.J., Kim, M.Y., Lee, J.H., You, J.C. & Jeong, S. Selection and stabilization of the RNA aptamers against the human immunodeficiency virus type-1 nucleocapsid protein. Biochem. Biophys. Res. Commun. 291, 925–931 (2002).
Bruno, J.G. & Kiel, J.L. Use of magnetic beads in selection and detection of biotoxin aptamers by electrochemiluminescence and enzymatic methods. Biotechniques 32, 178–183 (2002).
Bryant, K.F. et al. Binding of herpes simplex virus-1 US11 to specific RNA sequences. Nucleic Acids Res. 33, 6090–6100 (2005).
Noma, T. et al. A screening method for DNA aptamers that bind to specific, unidentified protein in tissue samples. Biotechnol. Lett. 28, 1377–1381 (2006).
Shamah, S.M., Healy, J.M. & Cload, S.T. Complex target SELEX. Acc. Chem. Res. 41, 130–138 (2008).
Shangguan, D. et al. Cell-specific aptamer probes for membrane protein elucidation in cancer cells. J. Proteome Res. 7, 2133–2139 (2008).
Mallikaratchy, P. et al. Aptamer directly evolved from live cells recognizes membrane bound immunoglobin heavy mu chain in Burkitt′s lymphoma cells. Mol. Cell Proteomics 6, 2230–2238 (2007).
Raddatz, M.-S.L. et al. Enrichment of cell-targeting and population-specific aptamers by fluorescence-activated cell sorting. Angew. Chem. Int. Ed. 47, 5190–5193 (2008).
Paul, A., Avci-Adali, M., Ziemer, G. & Wendel, H.P. Streptavidin-coated magnetic beads for DNA strand separation implicate a multitude of problems during cell-SELEX. Oligonucleotides 19, 243–254 (2009).
The authors would like to acknowledge many of our coworkers whose work is reported here. This work has been supported over the years by US National Institutes of Health and National Science Foundation and Florida State Biomedical Program grants. It is also supported by China 2009ZX10004-312 and a 985 project grant.
The authors declare no competing financial interests.
About this article
Cite this article
Sefah, K., Shangguan, D., Xiong, X. et al. Development of DNA aptamers using Cell-SELEX. Nat Protoc 5, 1169–1185 (2010). https://doi.org/10.1038/nprot.2010.66
Bone Research (2022)
Nature Protocols (2022)
Targeting loop3 of sclerostin preserves its cardiovascular protective action and promotes bone formation
Nature Communications (2022)
An impedimetric aptamer-based sensor for sensitive and selective determination of cardiac troponin I
Journal of the Iranian Chemical Society (2022)
Investigational New Drugs (2022)